Indian Natco to sell Bristol-Myer Squibb’s hepatitis C medicine in 112 countries

Indian pharmaceutical company Natco Pharma Limited has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol-Myer Squibb’s chronic hepatitis C medicine – Daclatasvir Dihydrochloride. Daclatasvir is used to treat hepatitis C virus genotype 3 patients. Natco will market generic Daclatasvir under…

Glenmark’s generic Multaq tablets wait for final FDA approval after tentative

Glenmark Pharmaceuticals Inc., has been granted tentative approval by the USFDA for its Dronedarone Tablets, 400 mg, the generic version Multaq Tablets, 400 mg of Sanofi-Aventis U.S. As the company explained in its press release, “Tentative approval” means that FDA has concluded that a drug product has met all requirement quality, safety and efficacy standards,…